This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Darden University of Virginia (USA)
-
Progressive Patents for Usage-Based Insurance
Doyle, Jacqueline L.; Ziegler, John S.Case DARDEN-OM-1578-EService and Operations ManagementThe material in this case presents Progressive Insurance as it faced important decisions regarding how to proceed with its usage-based insurance (UBI) initiatives, including the Snapshot device and related patents. Progressive had a head start on its competitors employing UBI pricing, but several competing insurance companies had been testing the waters with their own UBI products. In the case, Progressive considers a number of alternative uses ...Starting at €8.20
-
JWSM Construction: Building More Than a Rail Line
Doyle, Jacqueline L.; Linde, EricCase DARDEN-OM-1752-EService and Operations ManagementMarvin has just been tapped to assume control of a team of over 50 individuals tasked with completing a $40 million construction project over the next two years. His work package is part of a larger project to expand the footprint of a major city’s metropolitan railway network via construction of 10 miles of high-voltage rail and six large train stations. Although Marvin has worked at JWSM Construction, a general contractor, for three years, he’s...Starting at €8.20
-
The Sanofi-Aventis Acquisition of Genzyme: Contingent Value Rights
Matos, Pedro; Aleyev, Dmitriy; Xu, ChongCase DARDEN-F-1715-EFinanceThis case is designed for MBA students in M&A or derivatives courses. In January 2011, Sanofi-Aventis was finalizing its offer terms for acquiring Genzyme. The M&A valuation disputes were about the market potential of alemtuzumab, a drug in Genzyme’s pipeline, and how quickly Genzyme could resolve some of its manufacturing issues. To bridge the gap in their estimates, advisers had suggested an up-front cash payment and a contingent value right (C...Starting at €8.20
-
Sanofi-Aventis's Tender Offer for Genzyme
Eades, Kenneth M.; Matos, Pedro; Aleyev, Dmitriy; Xu, ChongCase DARDEN-F-1716-EFinanceIn October 2010, Henri Termeer, the chairman and CEO of Genzyme, received a letter from the CEO of Sanofi-Aventis announcing its intention to commence a tender offer for Genzyme. Termeer thought the offer undervalued Genzyme, given the number of promising new drugs in the company’s pipeline and the success of its current drug portfolio. The case focuses on the strategic and financial considerations of a large corporate acquisition. To estimate Ge...Starting at €8.20
-
Progressive Patents for Usage-Based Insurance -Teaching Note
Doyle, Jacqueline L.; Ziegler, John S.Teaching Note DARDEN-OM-1578TN-EService and Operations ManagementTeaching Note for productStarting at €0.00